Trojan horses and guided missiles: targeted therapies in the war on arthritis.
Despite major advances in the treatment of rheumatoid arthritis (RA) led by the success of biologic therapies, the lack of response to therapy in a proportion of patients, as well as therapy discontinuation owing to systemic toxicity, are still unsolved issues. Unchecked RA might develop into progressive structural joint damage, loss of function and long-term disability, disorders which are associated with a considerable health-economic burden. Therefore, new strategies are required to actively target and deliver therapeutic agents to disease sites in order to promote in situ activity and decrease systemic toxicity. Polymer-drug conjugates can improve the pharmacokinetics of therapeutic agents, conferring desirable properties such as increased solubility and tissue penetration at sites of active disease. Additionally, nanotechnology is an exciting modality in which drugs are encapsulated to protect them from degradation or early activation in the circulation, as well as to reduce systemic toxicity. Together with the targeting capacity of antibodies and site-specific peptides, these approaches will facilitate selective accumulation of therapeutic agents in the inflamed synovium, potentially improving drug efficacy at disease sites without affecting healthy tissues. This Review aims to summarize key developments in the past 5 years in polymer conjugation, nanoparticulate drug delivery and antibody or peptide-based targeting--strategies that might constitute the platform for the next generation of RA therapeutics.
Centre for Experimental Medicine &Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine &Dentistry, Queen Mary University of London, John Vane Building, Charterhouse Square, London EC1M 6BQ, UK.
Mathieu
M
Ferrari
Centre for Experimental Medicine &Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine &Dentistry, Queen Mary University of London, John Vane Building, Charterhouse Square, London EC1M 6BQ, UK.
Shimobi C
SC
Onuoha
Centre for Experimental Medicine &Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine &Dentistry, Queen Mary University of London, John Vane Building, Charterhouse Square, London EC1M 6BQ, UK.
Costantino
C
Pitzalis
D000818:Animals; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics / Q000378:metabolism*; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D058990:Molecular Targeted Therapy; D049329:Nanostructures / Q000008:administration & dosage; D011108:Polymers / Q000008:administration & dosage / Q000493:pharmacokinetics
D018501:Antirheumatic Agents; D011108:Polymers